Document is current
Any future updates will be listed below
-
Authors
Sadatsafavi, Mohsen https://orcid.org/0000-0002-0419-7862
FitzGerald, J. Mark
O’Byrne, Paul M.
Soliman, Mena
Sriskandarajah, Niroshan
Vicente, Colin
Golam, Sarowar Muhammad
-
Funding
Funding for this research was provided by:
AstraZeneca
- License Information
-
More Information
Article History
Received: 10 May 2021
Accepted: 28 September 2021
First Online: 12 October 2021
Declarations
:
: Not applicable.
: Not applicable.
: Mohsen Sadatsafavi has received honoraria from Boehringer Ingelheim, GlaxoSmithKline, and AstraZeneca, and research funding directly into his research accounts at the University of British Columbia from Boehringer Ingelheim and AstraZeneca (all unrelated to this work). J Mark FitzGerald reports grants and personal fees from AstraZeneca during the conduct of the study; grants paid to his institution from Canadian Institute for Health Research, National Institutes for Health, AllerGen NCE, AstraZeneca, Novartis, Boehringer Ingelheim, GlaxoSmithKline and Sanofi-Aventis outside the submitted work; personal fees from GlaxoSmithKline, Novartis, Sanofi Regeneron and Boehringer Ingelheim and is a Member of the Global Initiative for Asthma (GINA) Board and Science Committee. Paul M O’Byrne reports grants and personal fees from AstraZeneca during the conduct of the study; grants and personal fees from GlaxoSmithKline; personal fees from Menarini, Chiesi and Cipla; grants from MedImmune, AllerGen NCE, Genentech, Novartis, Merck and Bayer outside of the submitted work. Mena Soliman, Niroshan Sriskandarajah and Sarowar Muhammad Golam are employees of AstraZeneca. Colin Vicente is Managing Director of PIVINA Consulting Inc., which received funding from AstraZeneca to complete the cost-effectiveness analysis.
